FDA Panel Votes on Grail's Galleri Multicancer Blood Test
On Wednesday, Grail Inc. presented its Galleri blood test, a prescription-required screening that the company claims can identify as many as 50 different cancer types, to an FDA advisory panel. The Molecular and Clinical Genetics Panel deliberated on the potential endorsement of the test. Meanwhile, the question of Medicare coverage for Galleri is still unresolved as the panel considers its recommendation.
Key facts
- Grail Inc. developed the Galleri blood test.
- The company says the test can detect up to 50 types of cancer.
- The test is prescription-only.
- The FDA's Molecular and Clinical Genetics Panel voted on Wednesday.
- The panel voted on whether to recommend approval of the test.
- Medicare coverage for the test hangs in the balance.
Entities
Institutions
- Grail Inc.
- FDA
- Molecular and Clinical Genetics Panel
- Medicare
- NBC News
- US Food and Drug Administration
- Grail
Locations
- Hong Kong
- China
- United States
Sources
- Quartz —
- SCMP Lifestyle —
- Quartz —